On July 1, 2021, Chulho Park, Ph. D., provided notice to Oncotelic Therapeutics, Inc. of his intention to resign as the Chief Technology Officer of the company, to be effective immediately. Dr. Park will continue to provide services to the company as a consultant on a part-time and as-needed basis.